AACHEN, Germany--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the positive results of the first part of the Phase Ib study with the new short-acting intravenous anesthetic/sedative CNS 7056, which further strengthen the safety profile of the compound.
